CABA

Over the past six months (March 2026 - September 2026), several events influenced Cabaletta Bio's stock. In March 2026, the company reported Q4 and FY2025 financial results, projecting a Biologics License Application (BLA) submission in 2027 for rese-cel in myositis, anticipating no-preconditioning data in H1 2026, and expecting automated Cellares manufacturing in H1 2026. In May 2026, Cabaletta Bio presented preconditioning-free clinical data and automated manufacturing translational data for rese-cel at the ASGCT 2026 Annual Meeting, confirming initial Cell Shuttle automated manufacturing runs met release specifications. June 2026 saw the company announce new rese-cel data and development updates at the EULAR 2026 Congress, including encouraging early preconditioning-free lupus findings. In August 2026, Cabaletta Bio reported Q2 2026 financial results, confirming registrational RESET-Myositis data on track for mid-2027 to support a planned 2H27 BLA submission, selecting SSc-associated ILD as a second registrational cohort to initiate in Q4 2026, and incorporating a preconditioning-free approach in RESET-MG, while also expanding manufacturing partnerships with ElevateBio and Cellares. In September 2026, the company announced its participation in upcoming investor conferences, including the H.C. Wainwright 28th Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference.